PAREXEL EXPANDS PATIENT RECRUITMENT SERVICES WITH TECHNOLOGY TO ENHANCE RECRUITMENT STRATEGY AND EXECUTION
BOSTON, MA, June 12, 2007 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, is making patient recruitment and retention strategy, planning and execution more effective for clinical trial sponsors with an expanded offering that includes an expert recruitment team supported by new technology that it believes substantially improves patient recruitment performance.
In order to streamline and analyze all the disparate factors across the organization that can impact Last Patient In (LPI) recruitment goals, PAREXEL has organized a unique, global Start-up and Accelerated Recruitment Team (START). START relies upon a new suite of proprietary technologies and data assets to more accurately plan for recruitment milestones. The new Scenario Planning and Recruitment Calculator (SPARC™) integrates data from across the organization to help drug sponsors avoid costly delays caused by slow recruitment or poor patient retention. With these data, START is also able to implement pre-planned contingencies based upon ongoing information, helping to avoid potential problems.
According to Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics, PAREXEL, “Successfully achieving LPI milestones requires using all of the levers that PAREXEL, as a global CRO, has at its fingertips. Our expanded patient recruitment services let sponsors harness experience from some of the industry’s strongest recruitment specialists and the power of a solid technology platform that streamlines the entire process.”
Another critical aspect of PAREXEL's expanded recruitment capabilities is an enhanced investigator database that is used in conjunction with the SPARC to plan trials and identify high potential investigators.
“Investigator databases are often limited to lists of contact information, trial participation and therapeutic specialty. PAREXEL enhances these basic data with comprehensive information on patient enrollment success and other historic recruiting performance indicators. We believe we can provide sponsors all the facts they need to select the best sites for their trial,” commented Joshua Schultz, Vice President, Patient Recruitment, Clinical Research Services, PAREXEL.
For more information about START visit www.PAREXEL.com or visit Booth #724 at the DIA’s 43rd Annual Meeting.